Jasemine C. Chambers, PhD, JD
Deputy Administrator for External Affairs, United States Patent & Trademark Office (USPTO)

As Deputy Administrator, Dr. Chambers assists the Administrator in providing policy advice to the Director of the U.S Patent and Trademark Office (USPTO) on matters relating to intellectual property (IP) protection and enforcement, and IP-related trade issues, including proposed legislation and international activities.  She also oversees the day-to-day operations of a 100-member organization that comprises the Policy Division, the Office of Governmental Affairs, the Global IP Academy, the IP Attaché Program, and the Office of the Chief Economist.  

Dr. Chambers’ previous appointments at the USPTO include serving as Director of Technology Center 2900 where she oversaw the examination of design patent applications and as Director of Technology Center 1600 where she oversaw the examination of biotechnology and pharmaceutical patent applications.  In 2000, she became the first Asian female to be appointed to the USPTO’s Senior Executive Corps.

Dr. Chambers was instrumental in developing policy and practice related to the examination of gene sequences, stem cells, transgenic animals and gene therapies, as well as in developing examination guidelines and examiner training materials on the utility, written description and enablement requirements for biotechnological inventions.  She represented the USPTO in meetings of the Trilateral Biotechnology Working Group and worked on harmonizing examination practices.  Dr. Chambers also served as the USPTO's project coordinator in the creation of the Patent Cooperation Treaty Search and Examination Guidelines that was subsequently adopted by the World Intellectual Property Organization in 2004. 

A former law clerk to Chief Judge Randall Rader of the U.S. Court of Appeals for the Federal Circuit, Dr. Chambers has served on detail assignments at the White House Office of Science and Technology Policy, and the Department of State’s Office of IP Enforcement.  Prior to joining the USPTO, she was a Postdoctoral Fellow at the Duke University Medical Center, and a Senior Staff Fellow at the National Institutes of Health.

Dr. Chambers received a PhD in Molecular Biophysics from the Florida State University, and a JD with honors from the George Washington University Law School.  She is a member of the Maryland bar and the District of Columbia bar, and is admitted to practice before the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit.

Alan Morrison
Vice President, Regulatory Affairs, Amgen 

Alan Morrison, Vice President, leads Amgen’s International Regulatory Affairs & Safety functions of approx. 300 staff both in the UK and across more than 30 local affiliate offices worldwide.   As well as part of the Global Regulatory Affairs & Safety leadership, Alan is also key member of Amgen’s cross-functional International Management Committee, which sets and guides the International business overall strategic direction.

Alan joined Amgen in 2004, having previously held a number of regulatory affairs and safety positions at a number of companies including Baxter Bioscience. 

Alan is currently Chairman of the BioIndustry Association’s Regulatory Affairs Group and acting on a number of trade association committees related to biotechnology / biopharmaceuticals.

Gang Wang, PhD
Assistant Country Director, China Office, US Food and Drug Administration (US FDA) 

Dr. Gang Wang is currently the Assistant Director for the US FDA China Office in Beijing. At this position, he holds the responsibilities for regulatory issues, policy analysis, capacity building and collaborative programs related to drugs and biologics.

Prior to taking this position, Dr. Wang was a senior reviewer, lead inspector and an Expert Biologist in the Office of Compliance and Biologics Quality, Center for Biologics Evaluation and Research, FDA. His main responsibilities included reviewing and evaluating the CMC and CGMP issues of various biological license applications and supplements for biological drug products and conducting pre-licensure and pre-approval inspections of domestic and international manufacturing facilities for biological drug products. Dr. Wang is a peer-reviewed expert on CGMP and manufacturing of biological drugs, including vaccines, blood-derived products, cellular and gene therapy products, and stem cells.

Dr. Wang received his BS in biochemistry from Nanjing University in China and PhD in pharmacology and toxicology from Dartmouth Medical School in the U.S. He conducted his postdoctoral training in cancer immunotherapy at the National Cancer Institute in the National Institutes of Health. He was an Assistant Professor and Principal Investigator at the University of Texas M.D. Anderson Cancer Center prior to joining FDA in 2005.

Yang Wei
Deputy Director General, Drug Registration, State Food and Drug Administration (SFDA)

Mr. Yang Wei has been serving as the DDG of the Drug Registration Department of the SFDA since December 2008. Prior to this, he worked for the Jilin provincial Food and Drug Administration for 10 years, serving in numerous positions, including Director of Drug Safety, Director of Drug Registration, and Director of the General Office, among others.

Previously, he was the head of the Changchun Pharmaceutical Manufacturing Machinery Plant from 1996 to 1998. He has also worked at the Jilin Medicine Industry Institute.

Born in May 1962 in Jilin Province, DDG Yang graduated from Changchun Chinese Medicine College in Changchun, Jilin Province with a major in Chinese traditional medicine.

Friedhelm Blobel, PhD
President & Chief Executive Officer, SciClone Pharmaceuticals, Inc.

Friedhelm Blobel, PhD, has served as President, Chief Executive Officer and a Director of SciClone since June 2006. From July 2000 to 2006, Dr. Blobel was President, Chief Executive Officer and a Director of Gryphon Therapeutics, Inc., a South San Francisco-based biopharmaceutical company. Prior to joining Gryphon Therapeutics in July 2000, Dr. Blobel spent more than two decades as an executive with the Hoechst Group and the Boehringer Mannheim Group, including responsibilities in the areas of diabetes and in vitro diagnostics. His roles at these companies included Group President of several product divisions, Chief Technology Officer and General Manager in Tokyo, Japan of a marketing and sales joint venture between Boehringer and Yamanouchi Pharmaceuticals (now Astellas Pharma, Inc.), Senior Vice President of Research and Development Diabetes and Patient Care in Mannheim, Germany as well as in Indianapolis, Indiana.

Dr. Blobel earned his doctorate degree (“Dr.rer.nat.”; a PhD equivalent) with a dissertation in Biochemistry and Microbiology from the University of Hohenheim, Germany and holds an advanced degree in Chemistry from the University of Stuttgart, Germany.

Lian Yong (Leon) Chen, PhD
Founder & Managing Partner Frontline BioVentures

Dr. Chen is Founder and Managing Partner of Frontline BioVentures. He has over eighteen years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor. He is a member of the Expert Review Panel for the Chinese Central Government HR’s 1,000 Talent Project, and an adviser to BioBAY of Suzhou Industry Park. As a venture capital investor, his current and past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Director of Board, Acting CFO), Cathay Industrial Biotechnology (Director of Board), Hile Biopharma (Director of Board), Hua Medicine (Shanghai) (Director of Board), Innovent Biologics Ltd (Chairman), Adagene (Director of Board) and MDDF (Director of Board). As a management consultant, his past affiliations include McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area).

As a PhD scientist, he worked with Schering Plough (New Jersey), and is a key member of the discovery team of Zytia/Vytorin - a multi-billion drug. Dr. Chen was a Post-Doc at MIT, PhD (with top honor) from the University of Louvain, Louvain-La-Neuve, BS from Peking University. Leon holds 6 issued US Patents, and is co-author of the 14th and 15th Ernst & Young Biotechnology Annual Report.

Stanley C. Erck
President & Chief Executive Officer, Novavax, Inc.

Mr. Erck was named President and Chief Executive Officer of Novavax in April 2011. He became a Novavax Director in June 2009 and beginning in February 2010, served as its Executive Chairman of the Board. From 2000 to 2008, Mr. Erck was President and Chief Executive Officer of Iomai Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the Board of Directors of BioCryst Pharmaceuticals, MaxCyte, Inc. and the MdBio Foundation.

He received his undergraduate degree from the University of Illinois and his Masters in Business Administration from the University of Chicago Graduate School of Business.

Kewen Jin
Managing Director, Nimbus Innoworks

Mr. Kewen Jin is a serial entrepreneur in China's life science industry. He is currently Managing Director of Nimbus Innoworks, a life science incubator based in Suzhou. He was previously General Manager of Charles River Lab’s China company.

Mr. Jin has co-founded and served as CEO of several companies in CRO biotech and medical device.

He is an advisor to Suzhou Biobay, a leading life science park in China. He served as advisor to several multinational pharmaceutical companies, investment and consulting firms and NGOs.

He was a marketing and international operation executive with Wyeth from 1993 to 2000 , in the U.S. and in China. 

He was trained in medicine (Shanghai Jiaotong University), molecular biology (Rockefeller), and finance (Columbia).

He was granted the 2005 Magnolia Award by the Shanghai government. He served as the founding Chair of the Shanghai CRO Association. He was a Board member for Bayhelix.

He lives in Shanghai with three beautiful and brilliant women, his wife and two teenage daughters.

Jimmy Zhang
Greater China Lead, Licensing, Acquisitions & External Research, Worldwide Licensing & Acquisitions, Merck & Co. (MSD)

Dr. Jimmy Zhang is Greater China Lead, Licensing, Acquisitions & External Research at Merck & Co., and a member of Leadership Team of MSD China R&D.  He is responsible for Merck's licensing, acquisitions, research collaboration, alliance/partnership management and venture capital investments in Greater China. 

Before joining Merck, Jimmy was a Senior Vice President at Synergenics, LLC, a professional service and venture firm founded and led by Dr. Bill Rutter, one of the founding fathers and pioneers of the biotech industry.  Synergenics invests and manages early-stage companies in drug discovery, vaccine, diagnostics, and healthcare IT.  Jimmy is responsible for the business development and operations of Synergenics and some of its portfolio companies, and their businesses in China. 

Jimmy was previously a consultant at McKinsey & Company traveling and working in China, US and Germany, a registered patent agent in the Palo Alto office of Morrison & Foerster, and a project manager at Chiron Corporation (now part of Novartis). 

Jimmy received his BS in biochemistry from Nanjing University, and PhD in biomedical sciences from the University of Texas Southwestern Medical Center at Dallas, where he worked closely with two Nobel Laureates.  While studying his MBA in MIT Sloan School of Management, Jimmy was elected as the treasurer of MIT Graduate Student Council.  He was also a finalist of the 12^thAnnual MIT $50K Entrepreneurship Competition.

Jimmy has published in Cell, Nature, Neuron, and JBC, and holds multiple patents.  He’s a founding member and the currentChairman, Board of Directors of BayHelix Group, a prestigious non-profit organization of Chinese life sciences business leaders.  Jimmy is also the Strategic Advisor to both ChinaSF and China Committee of Bay Area Council, and a guest/adjunct professor at Tongji University, Shanghai.   Jimmy is a frequently invited speaker and panelist at bio-pharma conferences and hi-tech meetings on business development and doing business between US and China.  He is often quoted in both US and Chinese news media.

Robert (Rulei) Chen
Senior Director, Global Strategy & Partnering, Genor Biopharma Co. Ltd. 

Mr. Robert Chen is currently Senior Director, Head of Business DevelopmentatGenor Biopharma,a dedicated mAb product development and manufacturing company in China. His main responsibilities include business development, corporatestrategy, and intellectual propertymanagement.

He has more than 12 years of industrial experience in the biopharmaceutical industry.Prior to joining Wison, he worked for 2 years in a biopharmaceutical venture capital company, and developed his expertise in business development, company strategy and intellectual property management with two other biotechnology companies. Currentlythemost important part of his responsibilities is to help the company optimize its strategic positioning,andto establish strategic partnerships and future commercialization channels, both in China and globally. He has in-depth and unique understanding of how to effectively do strategic marketing and establish successful partnerships.

He finished his MS study of Neurobiology at the Chinese Academy of Sciences, and obtained his Bachelor of Biology from Wuhan University, both of which are among the top life science institutions in China. He also spent one year studying as a PhD candidate at the University of Florida, and completed a nearly one-year Executive Development Program (EDP) at Fudan University School of Management.

John Zhaolong Gong, PhD, MD 
CEO, BL Pharmaceuticals  

Dr. Gong joined BL Pharmaceuticals in March 2012. BL Pharma's mission is discover and develop innovative medicines to fulfill unmet medical needs through scientific research and collaborations with Chinese and western partners.

From 2008 to 2012, Dr. Gong served as CTO of JOINN Laboratories, he actively promoted and implemented international standards at JOINN, leading to the AAALAC accreditation in 2008, and US FDA inspection in 2009. Dr. Gong had ten years of US FDA regulatory experience in new drug development. He served as a Toxicology and Pharmacology Reviewer in the FDA's Center for Drug Evaluation and Research (CDER) and conducted primary and critical reviews of numerous IND and NDA applications for both small molecules and biologics.

Dr. Gong is a member of the Drug Safety Evaluation Committee of the Chinese Pharmaceutical Association, and an ad hoc specialist of AAALAC. He received his PhD in Toxicology from New York University in 1996 and a medical degree from Beijing Medical College in 1984.

H. Fai Poon, PhD
Director, Research & Development, Hisun Pharmaceutical

H. Fai Poon is currently R&D Director at Hisun Pharmaceutical. He previously worked at SAFC in which he collaborated with multiple biopharmaceutical companies (Samsung, Celltrion, Dong-A, Kaketsuken. Teva, Abbott, etc.) on their biologics manufacturing process improvement. Prior to SAFC, Dr. Poon worked at Roskamp Institute and lead their proteomic program. He has years of experience in the fields of industrial cell culture, bioanalytical research, bioinformatics and proteomics.

Dr. Poon completed his PhD in Biological Chemistry at the University of Kentucky, and his MBA at the University of South Florida. His MBA focus was on the application of lean management for laboratory efficiency improvement. He has published more than 30 peer-reviewed articles and authored three academic reviews, five book chapters and one book.

Dr. Poon is currently the associate editor for the Journal of Chemistry, Biochemistry and Molecular Biology, and associate editor-in chief for the International Journal of Bioinformatics and Biometrics. He has also served as a member of the editorial review board for the Scientific Journal International, the Society for Free Radical Biology and on the Medicine Young Investigator Awards (YIA) committee.

Boon Heon Tan
Managing Director, Biogen Idec, China

Tan Boon Heon is the Managing Director of Biogen Idec * China/Asia Expansion Markets, a region covering Greater China (China, Taiwan, Hong Kong), Korea and Southeast Asia. He is responsible for the commercial success, operational excellence and management of the teams in this region, and committed to introducing Biogen Idec’s pipeline of important specialty and rare disease drugs to these countries progressively.

Boon is an experienced pharmaceutical executive with a unique international experience spanning HQ, regional and country operations. He was previously with Merck, Sharp & Dohme (“MSD”), through its acquisition of Schering-Plough (“SP”), for more than 10 years. Boon’s former roles in MSD/SP included US Sales and Global Marketing, Asia-Pacific regional leadership, as well as various roles in China since 2008, including Head of Marketing, Regional General Manager of Shanghai, and Customer Solutions Director.

Prior to joining Biogen Idec in April 2012, Boon had a short stint with HR Consultancy firm Russell Reynolds as the head of the healthcare practice in China.

Boon started his professional career as a government official in the Singapore Economic Development Board, where he was last Assistant Head of the Life Sciences Division. In that role, Boon worked with other government agencies and companies to develop a world-class life sciences industry in Singapore.

A native Singaporean who is fluent in English and Mandarin Chinese, Boon holds Bachelors and Masters of Science in Engineering (Bioengineering) degrees from the University of Pennsylvania.  He is a commissioned infantry officer in the Singapore Armed Forces and still holds a reserve appointment. Boon is married and lives in Shanghai with his wife.

Rajesh Parekh
Director, Asia Pharmaceuticals & Medical Products Practice, McKinsey & Company 

Rajesh (Raj) is the leader of McKinsey’s Asia Pharmaceuticals and Medical Products Practice. He joined McKinsey’s Chicago office in 1996 and since 2005 has worked in our Shanghai office. He serves clients across the pharmaceutical and medical device and equipment sectors on their Asian businesses, with a focus on China, India, and Japan. Raj’s work spans a range of areas including growth strategy, sales & marketing and R&D. Raj led McKinsey’s internal knowledge effort to assess the impact of the recent healthcare reform on the medical device and equipment industry in China.

Recent medical device and equipment experience includes working with a global implantable medical device leader to develop breakthrough growth strategies for China and India; helping a leading hospital infusion equipment player assess attractiveness of the “value segment” in China and develop product and customer segmentation approach to capture the most attractive opportunities; and working with a leading medical device company to develop organization blueprint to manage the emerging market set of countries.

Raj holds a PhD in Chemical Engineering from University of Illinois at Urbana-Champaign and a BS in Chemical Engineering from University of California at San Diego.

Alec Reynolds
Commercial Director, Celgene Corporation

 Alec C. Reynolds is the Commercial Director of Celgene China.  He joined Celgene in 2007.  He has held several marketing roles for REVLIMID^® and has led the global marketing business planning function.  Previously, Alec worked for The Carlyle Group, a global private equity firm, and Morgan Stanley & Co.  He received an AB degree from Princeton University and an MBA from the University of Virginia Darden School. 

May-Kin Ho, PhD
Advisory Director, Goldman Sachs & Co.

Maykin is an advisory director to the firm. Previously, she was a biotechnology analyst and co-head of US Healthcare for Global Investment Research. Maykin joined Goldman Sachs in 1992 and was named managing director in 1998 and partner in 2002.

Maykin has been ranked the First or Second Team in Biotechnology by Institutional Investor and Greenwich Associates for over 10 years. She has also received numerous awards from The Wall Street Journal and Financial Times.

Prior to joining the firm, she held senior management positions in research, marketing and business development at Dupont-Merck Pharmaceuticals and Dupont De Nemours & Company.

Maykin serves on the board of The Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University and the Investment Committee of the Society for Neuroscience. She has also served on the Biological Chemistry Advisory Council at Harvard Medical School.

Maykin was a postdoctoral fellow at Harvard Medical School. She earned a PhD in Microbiology and Immunology from the State University of New York, Downstate Medical Center.

Sammy Jiang
Associate President, Luye Pharma Group Ltd.

Ms. Sammy (Chinese name: Hua Jiang) is the associate president of Luye Pharma Group, in charge of group development strategy, products portfolio management and the group’s international collaboration, including business development, company alliance, and international trade. She is also the vice general manager Shandong International bioscience park (BIOasis), in charge of overseas promotion and projects introduction work.

Ms. Jiang holds a Master‘s degree in Business Administration from Euromed Marseille Ecole de Management School (2007) and a Bachelor’s degree in Economics from Economy School, Fudan University (1998). She is the economist certified by China’s National Bureau of Personnel.

Ms. Jiang is the honorary director of ACLSTA (American Chinese Life Science Technology Association). She was listed in “China’s Top 99 Pharma Executives” in 2010, and won “the national excellent award 2010,” given by SAPA (Sino America Pharmaceutical Association).

Ms. Jiang is a freelance writer for Healthcare Executive magazine, China Pharmaceutical Technology Economics and Management magazine and the Chamber of Commerce’s Import & Export of Medicines & Health Products monthly magazine. She is also a part time lecturer for Yantai University Pharmaceutical College, and has been named in the top 10% of professors in the pharmaceutical school of Yantai University, as elected by the students.

Luo Xielong
President, Renhe Group

Mr. Luo Xielong has been President of Renhe Group since 2010. He previously served as Deputy General Manager of Beijing Pharmaceutical Co., Ltd., Central Research Institute, President of Beijing Pharmaceutical Co., Ltd., and Chairman of Chinese Medicine Research and Development Center from 2003 to 2012; GM, Peking University Health Science Center Yikang Technology Corporation and GM, Scrianen Pharmaceutical from 1994 to 2002; Deputy General Manager, Hong Kong Yizhou Group and GM, Shenzhen Yizhou High-tech Industry Co., Ltd. from 1990 to 1993; Division Chief, Division of Medical Service, Health Department, Hangzhou and Deputy Director, Zhejiang Administration Committee of Hospitals from 1983 to 1990.

In addition, he is a consultant to the Chinese Medicine Department, UNIDO, Vice President, CABA, Vice President, CJMST, Executive Vice President, CPEA, Director, Professional Committee of China Pharmaceutical Enterprise Internationalization, Director, Preparatory Committee of China Pharmaceutical Enterprise Innovative Preparation Industry Alliance, Executive Vice Chairman, China Biopharm CRO Alliance, Executive Vice Director, Cosmeceuticals Committee, China OTC Association, President and Honorary President, Industry & Commerce Beautyculture & Cosmetics Chamber, President, Beijing Zhongguancun Enterprise Association Of Biotech.& Pharma, Consultant for Industry Plan and Investment of China Medical City Taizhou, Group Leader, Biopharm 12th Five-year Plan Development Plan Research Group, Zhejiang Development and Reform Committee, Management and Investment Consultant, Hangzhou Biological Industrial & National High-tech Industrial Zone. Besides above mentioned posts, Mr. Luo has also served as an independent director and management consultant for dozens of domestic and overseas companies.

Mr. Luo graduated from Harbin Medical University and holds an EMBA both from Sino-European International Management Institute (Project and Investment Management) and Peking University Experimental Testing Center for Economics and Management (Business Management).  

• Governor Jay Inslee, Washington State
• Gary F. Locke, Ambassador of the United States of America to the People’s Republic of China
• Bian Zhenjia, Assistant Minister, CFDA
• Zhao Yajun, Director General, China Center for Pharmaceutical Exchange
• James C. Greenwood, President and CEO, Biotechnology Industry Organization 

• ETDZ
• James C. Greenwood, President and CEO, Biotechnology Industry Organization
• Ren Jun, CEO, Shanghai NewSummit Biopharma Group